Search results for " prognostic factors"

showing 10 items of 20 documents

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer.

2018

Background: Locally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival. Methods: We retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiv…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisDerived neutrophil-to-lymphocyte ratio; Head and neck squamous cell carcinoma; Inflammation-based prognostic scores; Neutrophil-to-lymphocyte ratio; Overall survival; Prognostic factors; Prognostic nutritional indexoverall survivalhead and neck squamous cell carcinomaderived neutrophil-to-lymphocyte ratio03 medical and health sciences0302 clinical medicineneutrophil-to-lymphocyte ratioInternal medicinemedicine1506Stage (cooking)Neutrophil to lymphocyte ratioOriginal ResearchUnivariate analysisbusiness.industryHead and neck cancerInduction chemotherapyprognostic factorsprognostic nutritional indexmedicine.diseaseHead and neck squamous-cell carcinomaClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisinflammation-based prognostic scoresbusinessESMO open
researchProduct

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classificatio…

2016

AbstractThe IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyLung NeoplasmsStagingMedizinPrognostic factors1102 Cardiovascular Medicine And HaematologyLung cancer; Prognostic factors; Staging03 medical and health sciences0302 clinical medicineSeer programmedicineHumansOncology & CarcinogenesisStage (cooking)Lung cancerNeoplasm Stagingbusiness.industryGeneral surgeryInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions1103 Clinical SciencesPrognosismedicine.diseaseInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasm stagingBiostatisticsLung cancer stagingLung cancerbusinessSEER Program
researchProduct

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

2011

Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum lev…

Liver CirrhosisMaleTime Factorsmedicine.medical_treatmentBiopsyMenopause PrematuremenopauseHepacivirusmedicine.disease_causeGastroenterologySeverity of Illness IndexRisk FactorsOdds RatioProspective StudiesTreatment FailureProspective cohort studymedicine.diagnostic_testGastroenterologyAge FactorsHormone replacement therapy (menopause)Hepatitis CMiddle AgedViral LoadImmunohistochemistryMenopauseItalyLiver biopsyRNA ViralFemaleInflammation Mediatorshcv svr menopauseViral loadAdultmedicine.medical_specialtyantiviral therapy; menopause; prognostic factors; hcv therapyGenotypeHepatitis C virusAntiviral AgentsRisk AssessmentSex FactorsInternal medicinehcvmedicineHumanshcv; ifn; menopauseHepatologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaOdds ratioHepatitis C Chronicmedicine.diseaseifnEndocrinologyLogistic ModelsbusinessBiomarkersGastroenterology
researchProduct

Factors that predict response of patients with hepatitis C virus infection to boceprevir

2012

Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. Methods Previously untreated patients (from the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior therapy (from the Retreatment with HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2 [RESPOND-2] trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration, 28–48 wk). A good response to interfer…

MaleCirrhosisMESH: Logistic ModelsHepacivirusMESH: Risk AssessmentGastroenterologyPolyethylene GlycolsMESH: Recombinant ProteinsMESH: Genotype0302 clinical medicineOdds RatioProspective StudiesMESH: Treatment OutcomeResponse to Therapy0303 health sciencesMESH: Polymorphism Single NucleotideGastroenterologyvirus diseases3. Good healthMESH: RNA ViralHCVDrug Therapy Combination030211 gastroenterology & hepatologyClinical Trial; Genetic; Prognostic Factors; Response to Therapy; Adult; Antiviral Agents; Biomarkers; Canada; Drug Therapy Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interleukins; Logistic Models; Male; Multivariate Analysis; Odds Ratio; Phenotype; Polyethylene Glycols; Polymorphism Single Nucleotide; Proline; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Viral Load; GastroenterologyViral loadmedicine.medical_specialtyMESH: InterleukinsGenotypeProlineInterferon alpha-2MESH: PhenotypeAntiviral AgentsRisk Assessment03 medical and health sciencesDrug TherapyGeneticMESH: RibavirinMESH: CanadaBoceprevirHumansPolymorphismMESH: ProlineMESH: HumansPrognostic FactorsInterleukinsMESH: AdultOdds ratiomedicine.diseaseUnited Statesdigestive system diseasesClinical trialLogistic ModelschemistryImmunologyMESH: FemaleBiomarkersTime Factorsmedicine.disease_causechemistry.chemical_compoundRisk FactorsInterferonMESH: Risk FactorsMESH: HepacivirusViralSingle NucleotideViral LoadHepatitis CClinical TrialRecombinant ProteinsEuropePhenotypeTreatment OutcomeCombinationRNA ViralFemaleMESH: Interferon-alphaMESH: Viral Loadmedicine.drugAdultMESH: Antiviral AgentsCanadaHepatitis C virusPolymorphism Single NucleotideMESH: Multivariate AnalysisInternal medicineRibavirinmedicineMESH: United States030304 developmental biologyMESH: Hepatitis CHepatologybusiness.industryRibavirinMESH: Time FactorsMESH: Biological MarkersInterferon-alpha[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Prospective StudiesMESH: MaleMESH: Odds RatioMESH: Drug Therapy CombinationMESH: Polyethylene GlycolsMultivariate AnalysisRNAInterferonsMESH: Europebusiness
researchProduct

Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

2015

Background: The clinical course of advanced adrenocortical carcinoma (ACC) is heterogeneous. Our study aimed primarily to refine and make headway in the prognostic stratification of advanced ACC.Patients and methods: Patients with advanced ENSAT ACC (stage III or stage IV) at diagnosis registered between 2000 and 2009 in the ENSAT database were enrolled. The primary end point was overall survival (OS). Parameters of potential prognostic relevance were selected. Univariate and multivariate analyses were carried out: model 1 'before surgery'; model 2 'post-surgery'.Results: Four hundred and forty-four patients with advanced ENSAT ACC (stage III: 210; stage IV: 234) were analyzed. After a medi…

MaleLung NeoplasmsENSATGastroenterologyPROPOSALClinical endpointAdrenocortical carcinomaENDOCRINEStage (cooking)Liver NeoplasmsIntraventricular blockHematologyMiddle AgedSERIESCANCEREuropeSurvival RateOncologymedicine.veinLymphatic MetastasisSURVIVALFemalemedicine.medical_specialtyUNITED-STATESBone NeoplasmsInferior vena cavaInternal medicineGRASmedicineadrenocortical carcinomaPrognostic factors adrenocortical carcinomaHumansNeoplasm InvasivenessSurvival rateAdrenocortical carcinoma; ENSAT; GRAS; Prognostic factors; Oncology; HematologyNeoplasm StagingRetrospective Studiesbusiness.industryCancerprognostic factorsRetrospective cohort studymedicine.diseaseAdrenal Cortex NeoplasmsSurgeryAdrenocortical carcinoma prognosisprognosisNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Pain intensity as prognostic factor in cancer pain management

2015

Aim The aim of this study was to prospectively assess the prognostic value of initial pain intensity and its duration in advanced cancer patients. Methods A prospective study was conducted in a sample of patients with cancer requiring pain control. Patients underwent standard analgesic strategies used in our palliative care units. Pain intensity was measured at admission (T0) and after successful dose titration or opioid/route switching within a week (Ts). Patients were also asked about their pain intensity reported 15 days before admission (T-15). Doses of opioids and duration of opioid use were recorded. Patients were also assessed for the presence of incident pain, neuropathic pain, alco…

MalePalliative careSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexPain assessmentNeoplasms80 and overProspective StudiesCancer painProspective cohort studyCancerPain MeasurementAged 80 and overPrognostic factorAnalgesicsPalliative CareAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Aged; Aged 80 and over; Analgesics; Analgesics Opioid; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Neuralgia; Pain; Pain Management; Pain Measurement; Palliative Care; Prognosis; Prospective Studies; Stress Psychological; Treatment Outcome; Severity of Illness Index; Anesthesiology and Pain MedicineAssessment toolMiddle AgedPrognosisAnalgesics OpioidAssessment toolsTreatment OutcomeAnesthesiaNeuropathic painFemalemedicine.drugOpioid responsePain assessmentAnalgesicPainOpioidPain intensityPrognostic factorsStressOpioid analgesicAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Anesthesiology and Pain MedicinemedicineHumansPain ManagementAdverse effectAgedbusiness.industryAnesthesiology and Pain MedicineLogistic ModelsOpioidOpioid analgesicsPsychologicalNeuralgiaCancer painbusinessStress Psychological
researchProduct

Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry

2019

Background Infants diagnosed with stage 4 s neuroblastoma commonly experience spontaneous disease regression, with few succumbing without response to therapy. We analyzed a large cohort of such infants enrolled in the Italian Neuroblastoma Registry to detect changes over time in presenting features, treatment and outcome. Methods Of 3355 subjects aged 0–18 years with previously untreated neuroblastoma diagnosed between 1979 and 2013, a total of 280 infants (8.3%) had stage 4 s characteristics, 268 of whom were eligible for analyses. Three treatment eras were identified on the basis of based diagnostic and chemotherapy adopted. Group 1 patients received upfront chemotherapy; Group 2 and 3 pa…

Malemedicine.medical_specialtyMultivariate analysisAdolescentmedicine.medical_treatmentLiver transplantationPrognostic factorsPediatricsCohort Studies03 medical and health sciencesNeuroblastoma0302 clinical medicineStage 4 s030225 pediatricsInternal medicineNeuroblastomamedicineHumansRegistries030212 general & internal medicineElevated ldhStage (cooking)Risk factorChildMale genderStage 4 sNeoplasm StagingChemotherapybusiness.industryResearchInfant Newbornlcsh:RJ1-570Infantlcsh:PediatricsPerinatology and Child Healthmedicine.diseaseSurvival RateInfants; Neuroblastoma; Prognostic factors; Stage 4 s; Pediatrics Perinatology and Child HealthItalyChild PreschoolFemalebusinessInfantsItalian Journal of Pediatrics
researchProduct

External validation of the preoperative Karakiewicz nomogram in a large multicentre series of patients with renal cell carcinoma

2012

Purpose: To perform a formal external validation of the preoperative Karakiewicz nomogram (KN) for the prediction of cancer-specific survival (CSS) using a large series of surgically treated patients diagnosed with organ-confined or metastatic renal cell carcinoma (RCC). Methods: Patient population originated from a series of retrospectively gathered cases that underwent radical or partial nephrectomy between years 1995 and 2007 for suspicion of kidney cancer. The original Cox coefficients were used to generate the predicted risk of CSS at 1, 2, 5, and 10 years following surgery and compared to the observed risk of CSS in the current population. External validation was quantified using meas…

Malemedicine.medical_treatmentKarakiewicz NomogramPredictive Value of TestNephrectomyNomogramPreoperative nomogram; Renal cell carcinoma; Prognostic Factors; Partial Nephrectomy; Radical nephrectomy; Metastatic renal cell carcinomaRisk FactorsRenal cell carcinomaRetrospective StudieChildAged 80 and overeducation.field_of_studyRadical nephrectomyPrognostic FactorKidney NeoplasmMiddle AgedKidney NeoplasmsNephrectomyRenal cell carcinomaSurvival RateItalyPreoperative nomogramPredictive value of testsPreoperative PeriodFemalePartialHumanAdultmedicine.medical_specialtyKarakiewicz Nomogram; Renal cell carcinoma; cancer specific survivalAdolescentUrologyPopulationMetastatic renal cell carcinomacancer specific survivalUrologyYoung AdultPredictive Value of TestsmedicineHumanseducationSurvival rateCarcinoma Renal CellRetrospective StudiesAgedPrognostic Factorsbusiness.industryRisk FactorRetrospective cohort studyNomogramMetastatic renal cell carcinoma; Nephrectomy; Preoperative nomogram; Prognostic Factors; Renal cell carcinomamedicine.diseaseNomogramsbusinessKidney cancer
researchProduct

Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.

2011

OBJECTIVES To investigate cancer-related outcomes and prognostic factors of papillary renal cell carcinoma (pRCC) in a large multicentre data set. Oncological outcome and prognostic factors of pRCC have been limitedly evaluated in comparison with the most common RCC subtype, clear cell RCC. PATIENTS AND METHODS From a multicentre retrospective database, including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007, 577 patients with pRCC were identified. Univariable and multivariable Cox regression models were performed to identify prognostic factors predictive of recurrence-free survival (RFS) and cancer-specific survival (CSS) after surge…

Malerenal cell carcinomaTime FactorsPapillary renal cell carcinoma; Prognostic factorsPrognosiFEATURESkidney cancer; papillaryrenal cell carcinoma; papillary adenocarcinoma; prognostic factorspapillary renal cell carcinomaNephrectomyCLASSIFICATIONFollow-Up Studiecancer-specific survivalpapillaryRisk FactorsRetrospective StudieCause of DeathPrevalenceHumansrecurrence-free survivalprognostic factorCarcinoma Renal CellTYPE-1Proportional Hazards ModelsRetrospective StudiesNeoplasm StagingAcademic Medical Centerspapillary adenocarcinomaRisk Factorkidney cancerKidney Neoplasmprognostic factorsMiddle AgedPrognosisTUMORSKidney NeoplasmsHISTOLOGIC SUBTYPESPrognostic factors in a large multi-institutional series of papillary renal cell carcinoma.Survival RateAcademic Medical CenterItalySURVIVALProportional Hazards ModelFemaleprognostic factors; papillary renal cell carcinoma; recurrence-free survival; cancer-specific survivalFollow-Up StudiesHuman
researchProduct

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

2011

Study Type - Outcomes (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? About 80% of RCCs have clear cell histology, and consistent data are available about the clinical and histological characteristics of this histological subtype. Conversely, less attention has been dedicated to the study of non-clear cell renal tumours Specifically, published data show that chromophobe RCC (ChRCC) have often favourable pathological stages and better nuclear grades as well as a lower risk of metastasizing compared with clear cell RCC (ccRCC). Patients with ChRCC were shown to have significantly higher cancer-specific survival (CSS) probabilities compared with ccRCC. H…

Malerenal cell carcinomachromophobe RCC; prognostic factors; Carcinoma; Nephrectomy; Prognosis; Renal cellKaplan-Meier EstimateChromophobe renal cell carcinomaCarcinoma; Chromophobe; Nephrectomy; Prognosis; Renal cellchromophobe RCCNephrectomyHumansRenal cellCarcinoma Renal CellChromophobecarcinoma; renal cell; chromophobe; prognosis; nephrectomyCarcinomaKidney Neoplasmprognostic factorsMiddle AgedPrognosisKidney Neoplasmsoncological outcamesrenal cell carcinoma; prognostic factorsoncological outcomes and prognostic factorsChromophobe renal cell carcinoma; prognostic factors; oncological outcamesFemaleprognosiHuman
researchProduct